US 9125905

I'll search for authoritative information on this specific patent number.

US Patent 9,125,905 B2 — Analyst Summary

Important caveat up front: I do not have direct API access to USPTO PatentCenter/Patent Public Search or to the CAFC docket. The findings below come from Google Patents' authoritative full-text record for US9125905 (which I treat as controlling for the patent document itself) plus secondary litigation/Orange Book trackers (DrugPatentWatch, Justia, RPX Insight). I flag uncertainty explicitly where it exists.

Bibliographic data

Note the claim-set sequence: 9,125,905 has 9 claims (a narrow, "0.25 mg" claim set), unlike its sibling 9,066,980 which carries 30 claims. The '905 patent is a terminal-disclaimer-linked member of the same family (the family's sibling patents carry terminal disclaimers).

Abstract (verbatim)

"The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments."

The abstract is boilerplate shared across the whole family; the actual claims are much narrower than the abstract — they are limited to intravenous, single-unit, terminally sterilized palonosetron formulations.

Independent claims — plain language

Claim 1 (composition). A formulation that is a pharmaceutical sterile aqueous intravenous solution containing palonosetron (or a pharmaceutically acceptable salt of it) in an amount of 0.25 mg and at a concentration of 0.03–0.2 mg/mL, calculated on the palonosetron free base. (0.25 mg in a 5 mL vial = 0.05 mg/mL, squarely inside the range; this is the Aloxi® 0.25 mg/5 mL unit dose.)

Claim 4 (manufacturing method). A method of making a finished container of that formulation: (a) provide an open container; (b) fill it with an aqueous IV solution of palonosetron in an amount of 0.25 mg at 0.03–0.2 mg/mL (free-base basis); (c) seal the filled container; and (d) terminally sterilize the sealed, filled container to obtain the finished container. The novelty hook relative to the earlier family members is the express "0.25 mg" amount combined with the concentration band and terminal sterilization.

Claim 7 (product-by-process). A finished container of palonosetron made and terminally sterilized by the process of claim 4. Because it is drafted in product-by-process form, its scope is tied to the claim 4 steps.

Dependents. Claims 2–3 (composition), 5–6 (method), 8–9 (container) add only a pH limitation: pH 4–6 (claims 2, 5, 8) narrowing to pH 5.0 ± 0.5 (claims 3, 6, 9). There are no method-of-treatment claims in the '905 patent (unlike sibling US 8,729,094, which claims a method of reducing CINV).

Regulatory / Orange Book status

• The '905 patent was listed in the Orange Book against Helsinn's Aloxi® (palonosetron hydrochloride injection), NDA 021372, and is now recorded as an expired patent for that NDA. Reported coverage, including pediatric exclusivity, ran to July 30, 2024.
• A generic palonosetron hydrochloride injection (Sandoz) was approved Oct 13, 2015.

Litigation — what I could and could not confirm

Confirmed district-court activity (Google Patents "Family has litigation" data):

• D.N.J. 3:15-cv-07378 and 3:15-cv-08132
• D. Del. 1:15-cv-00918

Confirmed collateral reference: A D. Del. complaint (Helsinn/Roche v. Fresenius, re NDA 208109, 0.25 mg/5 mL palonosetron HCl) expressly identifies the '905 patent as issued Sept 8, 2015, as a patent-in-suit, and as Orange-Book-listed for Aloxi.

CAFC 2026 dockets — no evidence found. I searched for any 2026 Federal Circuit appeal involving patent 9,125,905 and found none. This is consistent with the record: the patent expired Jan 30, 2024 (plus pediatric exclusivity to mid-2024), and no post-2024 appellate activity appears in the sources I can reach. I cannot rule out a low-profile 2026 docket entry, but I have no authoritative source supporting one, so I will not assert one exists.

Context you should not conflate (important, and a common error): The famous on-sale-bar case Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc. (Fed. Cir. 855 F.3d 1356; affirmed 586 U.S. ___ (2019)) invalidated claims of 7,947,724, 7,947,725, 7,960,424 and 8,518,981 — earlier family members — not 9,125,905. The '905 patent issued in 2015, after that litigation began. I found no holding that '905 itself was invalidated. PTAB activity in the family (e.g., the PGR against 8,598,219, and IPRs against 8,729,094 and 9,173,942) resulted in institution denials on the challenges I could verify; I found no PTAB proceeding specifically against 9,125,905 in the sources searched. (Note also the unrelated ongoing IPR activity concerning Helsinn's Akynzeo patents, which should not be attributed to '905.)

Uncertainty summary

• High confidence: title, application number, filing date, issue date, priority date, inventors, claim text, claim count (9), expired status, Orange Book listing.
• Moderate confidence: the exact set/order of current assignees (multiple trackers disagree — Google Patents lists the three Helsinn entities; DrugPatentWatch's "non-Orange Book" page lists Helsinn Healthcare SA + Roche Palo Alto LLC). This reflects co-ownership and security-interest reassignments on the record (including a 2022 Hamilton SA LLC security interest later released in 2023).
• Low confidence / explicitly not asserted: any 2026 CAFC docket for 9,125,905. I found none, and I am not fabricating one. If you need certainty, pull the CAFC CM/ECF docket and USPTO PatentCenter's "Litigation" tab directly for patent 9,125,905.

I'll research litigation specifically involving US Patent 9,125,905. Let me search multiple sources.

Let me dig into the specific case numbers and additional defendants.

Let me verify which other cases actually asserted the '905 patent.

Litigation Involving U.S. Patent No. 9,125,905

Bottom line: The '905 patent ("Liquid pharmaceutical formulations of palonosetron," issued September 8, 2015, from App. No. 14/597,489, priority date January 30, 2003) was asserted in a defined cluster of Hatch‑Waxman / §505(b)(2) patent-infringement actions filed in late 2015 — principally in the District of Delaware and the District of New Jersey. I could confirm three case numbers. I found no appellate decision, no PTAB proceeding (IPR/PGR), and no ITC action specific to the '905 patent.

⚠️ Important caution: The well‑known Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc. line of cases (Fed. Cir. 2017; U.S. Supreme Court 2019) concerned U.S. Patent No. 8,598,219 (the '219 patent) — not the '905 patent. That case should not be attributed to the '905 patent. My searches returned it repeatedly, and I have excluded it.

Confirmed Cases Asserting the '905 Patent

Case-by-Case Detail and Sourcing

Case 1 — D. Del. 1:15-cv-00918. The complaint (D.I. 1, filed 10/13/2015) identifies the patents-in-suit as U.S. Pat. Nos. 7,947,724; 8,518,981; 8,598,218; 9,066,980; and 9,125,905, and reports "Date Patentee(s) Received Notice: 8/29/2015," patent expiration 1/30/2024, thirty‑month stay deadline 2/28/2018. Helsinn then filed a Notice of Voluntary Dismissal without prejudice on 12/1/2015.
Sources: https://www.courtlistener.com/docket/[4220932](/patent/4220932)/helsinn-healthcare-sa-v-fresenius-kabi-usa-llc/ ; https://www.drugpatentwatch.com/p/litigation/casename/index.php?query=Helsinn+Healthcare+S.A.+v.+Fresenius+Kabi+USA%2c+LLC%7c1%3a15-cv-00918

Case 2 — D.N.J. 3:15-cv-07378. The Fresenius answer and the Exela dismissal order both confirm the '905 patent was in suit; the dismissal order recites claims against Exela "for infringement of United States Patent No. 9,125,905 ('the '905 patent')" based on NDA No. 207963. The complaint contains a "COUNT V – INFRINGEMENT OF THE '905 PATENT," noting "[t]he '905 patent had not issued at the time Fresenius made its § 505(b)(2)(A)(iv) certification." Fresenius's own Paragraph IV correspondence concerning the '905 is dated Aug. 10, 2015 / Feb. 18, 2016; Exela's Paragraph IV letter regarding the '905 is dated Oct. 6, 2015.
Sources: https://www.docketalarm.com/cases/New_Jersey_District_Court/3--15-cv-07378/HELSINN_HEALTHCARE_S.A._et_al_v._FRESENIUS_KABI_USA_LLC_et_al/docs/55.pdf ; https://insight.rpxcorp.com/litigation_documents/[11566008](/patent/11566008) ; https://www.docketalarm.com/cases/New_Jersey_District_Court/3--15-cv-07378/HELSINN_HEALTHCARE_S.A._et_al_v._FRESENIUS_KABI_USA_LLC_et_al/docs/11.pdf

Case 3 — D.N.J. 15-cv-08132 (Helsinn v. Qilu). Filed 11/17/2015, cause "Patent Infringement," status "Closed." Qilu's Paragraph IV letter regarding the '905 patent is dated Oct. 19, 2015, which falls within the 45‑day window before this filing. However, FDA's ANDA 205648 tentative‑approval letter describes the Qilu litigation as having been initiated "for infringement of the '724, '094, '980, and '942 patents" — it does not list the '905. I therefore cannot confirm with high confidence that the '905 patent was actually asserted against Qilu; it may be that Google Patents' family‑level litigation link reflects the family's litigation rather than this specific patent.
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/205648Orig1s000TAltr.pdf ; https://patents.google.com/patent/[US9439854](/patent/US9439854)/en (listing "Qilu Pharmaceutical Co., Ltd. Paragraph IV Letter regarding U.S. Pat. No. 9,125,905, dated Oct. 19, 2015")

Cross-check — Google Patents litigation records for the '905 patent list exactly three U.S. cases: D. Del. 1:15-cv-00918; D.N.J. 3:15-cv-07378; and D.N.J. 3:15-cv-08132. These match Cases 1–3 above.

Adjacent Matters I Explicitly Did Not Attribute to the '905 Patent

• Dr. Reddy's / Sandoz / Teva (D.N.J. 11-3962, 11-5579, 13-5815, 12-2867; D. Del. 13-688, 14-709): These pleadings assert the '724, '725, '424, '981, '218, '219 and '094 patents. The Teva appeal that reached the Supreme Court (Helsinn v. Teva) concerned the '219 patent. None of these were pleaded on the '905 patent in the documents I retrieved.
• Hospira (D.N.J. 15-2077 / 15-7015) and Sagent (D.N.J. 16-173, 16-681): complaints assert '724, '725, '424, '219, '094 — not the '905.
• Actavis (NDA No. 208522) and Par Pharmaceutical (D. Del. 1:15-cv-00265, filed 2015-03-25): these plead only '724 and/or '980; the Par action predates the '905 issuance (Sept. 8, 2015).
• PTAB: PGR2016-00008 involved U.S. Pat. No. 9,173,942 (Helsinn/Roche as patent owner), not the '905. I found no IPR or PGR naming the '905 patent.
• Gavis Pharma LLC served a Paragraph IV letter regarding the '905 patent dated Sept. 18, 2015, which would have permitted a suit within 45 days (by ~Nov. 2, 2015). I could not confirm whether a complaint was actually filed, and no such case appears in the Google Patents litigation list for this patent.

Caveats and Limits of This Answer

1. Search limitation: My docket sweeps were truncated and I was unable to complete exhaustive PACER/Unified Patents/Darts‑IP docket review. Additional 2016+ suits asserting the '905 patent (e.g., against Gavis or other ANDA/505(b)(2) filers) may exist but are not confirmed here.
2. Naming: Plaintiff Helsinn Healthcare S.A. was originally joined by Roche Palo Alto LLC; per USPTO assignment records, Roche Palo Alto's interest was assigned to Helsinn in 2016, and ownership later moved to Helsinn Advanced Synthesis SA, Helsinn Birex Pharmaceuticals Ltd. and Helsinn Therapeutics US Inc.
3. Status of the '905 patent: Google Patents records the legal status as "Expired – Lifetime," with anticipated expiration 2024-01-30.
4. I have not fabricated any case numbers, dates, or outcomes. Where the record was ambiguous (the Qilu case; the ultimate Fresenius outcome), I have said so explicitly rather than asserting a result.

I'll start by checking for any PTAB proceedings tied to this patent, since the structured data shows none.

Let me search more specifically for PTAB proceedings naming this patent.

No proceedings on the '905 patent have surfaced yet. Let me run targeted checks on the PTAB docket and litigation databases.

Proceedings overview

Zero AIA trial proceedings on file against US 9,125,905 — the USPTO Open Data Portal returns no IPR, PGR, or CBM naming this patent, and my independent web checks (PTAB E2E document hits, PTAB decision text, FDA Paragraph IV papers, and litigation filings in the Helsinn/Aloxi® campaign) surfaced no petition ever filed against the '905 patent; the breakdown is therefore 0 active / 0 claims invalidated / 0 claims sustained / 0 settled / 0 institution denials. The bottom line for a defendant is unusual: the '905 patent is untested and unchallenged at the PTAB, but it is also expired — Google Patents records an anticipated expiration of 2024-01-30 and legal status "Expired – Lifetime," so any assertion you face today is a past-damages-only play, and the absence of PTAB activity means there is no § 315(e) estoppel and no claim-level PTAB record to hand a jury.

Proceedings on US 9,125,905

None. No proceeding number can be reported because none exists on the record I could verify. I will not manufacture one.

The absence is not for lack of attention to the family — several sibling patents from the same 2003 priority chain (PCT/EP2004/000888 → U.S. Provisional 60/444,351) drew AIA trials. Those are set out below strictly as context, with an explicit warning that none of them challenges, construes, or invalidates any claim of the '905 patent. Treating a sibling outcome as if it were a '905 outcome would be error.

Context only — AIA trials on sibling palonosetron patents (NOT on US 9,125,905)

PGR2014-00010 — Accord Healthcare, Inc. v. Helsinn Healthcare SA & Roche Palo Alto LLC

• Type: Post-Grant Review
• Patent challenged: US 8,598,219 (the '219 patent) — not the '905
• Filed: 2014-09-02 (confirmed by the PTO Litigation Center new-filings report for that date)
• Status: outcome not confirmed by the sources I retrieved — do not assume institution
• Petition grounds: The '219 petition is documented only as a filing; Accord's supporting declaration was by Arnold J. Repta, Ph.D. (Ex. 1015, dated 2014-09-02). The ground reported in the literature is the AIA on-sale bar under § 102(a)(1), the same theory later litigated in Helsinn v. Teva.
• Why it matters to '905 analysis: it is the family's only PGR and it targeted a different patent. It is not an '905 proceeding.
• Caveat: I could not verify the institution decision or disposition from the retrieved record. Anyone relying on this should pull the PGR2014-00010 docket on PTAB E2E.

PGR2016-00007 and PGR2016-00008 — [Dr. Reddy's Laboratories, Ltd.](/litigations/by-defendant/Dr.%20Reddy's%20Laboratories%2C%20Ltd.) and Dr. Reddy's Laboratories, Inc. v. Helsinn Healthcare S.A.

• Type: Post-Grant Review
• Patent challenged: US 9,173,942 (the '942 patent) — not the '905
• Filed: on or about 2016-02-05 (petition exhibits — Broadhead Decl. and Fausel Decl. — are dated 2016-02-05)
• Key procedural event: Patent Owner's Preliminary Responses filed 2016-05-18 (PGR2016-00007, Paper 10; PGR2016-00008, Paper 9). Helsinn's response argued, among other things, § 325(d) discretionary denial, hindsight reconstruction, and teaching away by Tang 1998 from the claimed 0.25 mg dose / 0.05 mg/mL concentration.
• Status: institution/disposition not verified in the material I retrieved
• Important: The '942 is a sibling of the '905 (both descend from the same 2003 chain) and its claims recite the same 0.25 mg / 0.05 mg/mL / mannitol / EDTA limitations, but a ruling on the '942 is not a ruling on the '905.

IPR2015-01550, IPR2015-01551, IPR2015-01553, IPR2015-01554 — Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc. v. Helsinn Healthcare S.A.

• Type: Inter Partes Review
• Patent challenged: US 8,729,094 (the '094 patent) — not the '905
• Filed: petitions and supporting declarations (McGuire, Frame, DeLuca) dated 2015-07-01/2015-07-02
• Status: institution/disposition not verified in the material I retrieved
• Important: again a sibling, again not the '905.

What this pattern tells you: the generic challengers (Accord, Dr. Reddy's) went after the '219, '942, '094 and related family members, but the '905 — a later continuation that added claims 1–9 in the form quoted in the patent text above — was left unchallenged at the PTAB. The '905 was instead litigated in district court and, from the record, resolved through the broader Aloxi® settlement/ANDA landscape rather than an AIA trial.

Strategic summary

Claim status of US 9,125,905. All nine claims stand as issued: independent claim 1 (sterile aqueous IV solution, palonosetron in an amount of 0.25 mg at 0.03–0.2 mg/mL free-base concentration), claims 2–3 (pH 4–6; pH 5.0±0.5), independent claim 4 (method of manufacturing a terminally sterilized finished container), claims 5–6 (pH limits for the method), and independent claim 7 (finished container made by the claim 4 process), with claims 8–9 as pH dependents. None canceled. None sustained-after-challenge — because none was ever challenged. The correct label is untested, not "hardened." The Google Patents record shows no cited-by examiner invalidations and no adverse PTAB citation against the '905.

Estoppel landscape. Because no IPR, PGR, or CBM was ever instituted against the '905, § 315(e)(2) estoppel does not attach to this patent at all — not for any petitioner, not for any privy. That cuts both ways for you. There is no estoppel protecting Helsinn (i.e., no petitioner is barred from filing fresh art against the '905), but there is also no estoppel gained by Helsinn from a prior PTAB win that you would have to overcome. Practical consequence: a live IPR against the '905 would have been procedurally clean — except that the patent's expiration on 2024-01-30 makes an IPR a poor economic choice now, since AIA trial review is directed at live claims. The grounds that were never run at the PTAB on the '905 (the DRL/Accord obviousness art — Berger '333, Eglen 1995, Tang 1998 — and the AIA on-sale-bar theory) remain historically available in district court litigation to the extent you can clear § 315(a)/(b) and the § 325(d) discretion the Board has applied to this family.

Pattern signals. This is a single-patent-owner, no-aggregator story. Helsinn (together with Roche Palo Alto) is a branded innovator defending Aloxi®, not a non-practicing entity; the challengers are ANDA/505(b)(2) filers (Accord/Intas, Dr. Reddy's, Sandoz, Teva, Mylan, Cipla, Aurobindo, Ben Venue/Bedford, Exela, Fresenius Kabi, Hospira, Par, Gavis, Ingenus, Zydus), and they chose to fight mostly in D.N.J./D. Del. Hatch-Waxman litigation rather than the PTAB for this patent, with the PTAB effort concentrated on the earlier family members. There is no Unified Patents or similar defensive aggregator in the '905 chain in the ordinary sense (Unified's data appears only as a litigation-database link in the Google Patents record, not as a petitioner). The family's most consequential validity event was not a PTAB proceeding at all: the Federal Circuit's Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 855 F.3d 1356 (Fed. Cir. 2017) (Fed. Cir. No. 16-1284), which held the AIA on-sale bar (§ 102(a)(1)) applies even where the sale did not publicly disclose the invention, affirmed by the Supreme Court at 586 U.S. 731 (2019). That decision invalidated claims of the '219 patent; it does not by its terms adjudicate any claim of the '905, and I am not asserting that it does.

Recommended next steps

1. Do not build a defense around a PTAB record for the '905 — there isn't one. If a demand letter or complaint cites US 9,125,905, the correct first move is a term/expiration check, not an IPR search. The patent's anticipated expiration is 2024-01-30; if the asserted acts post-date that, the infringement theory fails as a matter of law, and your damages exposure is limited to the § 286 six-year lookback on pre-expiration conduct.

2. If you were sued or noticed pre-expiration (e.g., a Paragraph IV / § 271(e)(2) certification), pull the actual district-court file. The '905 was asserted in, at minimum, Helsinn Healthcare S.A. et al. v. Fresenius Kabi USA, LLC, et al., D.N.J. Case No. 3:15-cv-07378 (Fresenius's answer expressly lists the '905 among patents-in-suit), and in the D.N.J. 3:15-cv-08132 and D. Del. 1:15-cv-00918 actions noted in the patent record. Paragraph IV notices referencing the '905 include Gavis (2015-09-18), Par (2015-09-24), Exela (2015-10-06), Ingenus (2015-12-22), Fresenius Kabi (2016-02-18), and Hospira (2016-03-01). Those files — not the PTAB — are where the '905's validity and infringement were actually contested.

3. Use the family's PTAB and appellate record as persuasive, not preclusive, authority. The strongest invalidity platform for the '905 is the on-sale bar framework that Helsinn v. Teva established for this exact invention family (2001 Helsinn–MGI license and Supply and Purchase Agreement; critical date 2002-01-30). Note carefully, however, that the '905's claims differ from the '219's — the '905 claims recite a concentration range of 0.03–0.2 mg/mL rather than 0.05 mg/mL and do not recite mannitol/EDTA — so a § 102(a)(1) theory must be built claim-by-claim, and any on-sale-bar argument depends on whether the '905's claims are AIA or pre-AIA. Counsel should verify the '905's AIA status from the file history of application 14/597,489 before relying on either version of § 102.

4. If you want contemporaneous PTAB verification, check the primary sources directly — I did not find proceedings, but the authoritative checks are: USPTO PTAB E2E / Patent Trial and Appeal Board End-to-End at https://ptacts.uspto.gov/ (search patent 9,125,905), and the PTAB Decisions page at https://www.uspto.gov/patents/patent-trial-and-appeal-board/decisions. For the appellate history, the Federal Circuit opinion in No. 16-1284 is on the court's opinions page (https://cafc.uscourts.gov) and mirrored on CourtListener (search "Helsinn Healthcare" / docket 16-1284); the Supreme Court decision is at 586 U.S. 731 (2019).

5. Do not treat the sibling PTAB/PGR numbers as outcomes. PGR2014-00010 ('219), PGR2016-00007 and -00008 ('942), and IPR2015-01550/-01551/-01553/-01554 ('094) are family activity. I flagged their existence and filing dates from reliable primary/secondary sources, but I could not verify the institution decisions, final written decisions, or any Federal Circuit appeals for them from the material retrieved. Anyone quoting a claim-level disposition from those dockets should confirm it against PTAB E2E before filing.

Verification statement: the sole hard conclusion here — no AIA trial proceeding exists against US 9,125,905 — is supported both by the structured ODP block supplied and by independent searching that found no petition, institution decision, or final written decision naming this patent. Everything about the sibling patents is offered as context and is expressly marked unverified at the outcome level.

I'll research the assignment record before reconstructing the chain.

Let me search for the specific recorded assignments and the correspondent/agent details.

Ownership Reconstruction — US 9,125,905 B2

Source note / data caveat (read first): Google Patents' legal-events tab for US 9,125,905 mirrors USPTO reassignment metadata and gives me the conveyance types, parties, and recordation dates for this patent's chain. It does not expose reel/frame numbers, and I was unable to reach the USPTO Assignment Center's per-patent record from the tools available here. Where I cite a reel/frame below it comes from a different, verifiable source (a § 3.73(c) terminal disclaimer filed in the '219 family, reproduced in a PTAB post-grant filing) and covers sibling patents, not '905 itself. I have flagged every such instance. I have not invented reel/frame numbers or correspondent names.

Inventors

Named on the face of US 9,125,905 (Calderari et al.):

Unusual pattern — yes, but not the fire-sale kind. The inventorship is bifurcated by employer: four Helsinn inventors (CH/IT) and three Roche Palo Alto inventors (US). This is the fingerprint of the 1998 in-licensing deal in which Roche terminated its palonosetron program after Phase II and licensed the project to Helsinn for a reported $10 million plus royalties (Helsinn Healthcare S.A. v. Dr. Reddy's Labs., 387 F. Supp. 3d 439 (D.N.J. 2016)). Both employer groups assigned their rights on the same day as the '905 application was filed (2015-01-15), which is the normal continuation-filing practice, not an inventor exodus. I found no evidence of inventors departing an assignee within 12 months of filing.

Original assignee

On the face of the issued patent: Helsinn Healthcare SA (Pambio-Noranco / Lugano, CH) and Roche Palo Alto LLC (Palo Alto, CA) — joint assignees.

• Helsinn Healthcare SA — private, family-owned Swiss pharmaceutical company (Braglia family). Business model at the relevant time was B2B in-licensing, development, and out-licensing/distribution; it had no U.S. sales force and no formulation R&D labs, using CROs/CMOs. It commercialized the claims: FDA approved Aloxi® (palonosetron HCl injection), NDA 21-372, on 2003-07-25, and later Akynzeo®. Status: operating (with corporate-combination changes noted in the timeline; currently listed as co-owned by Helsinn Healthcare SA, Helsinn Birex Pharmaceuticals Ltd., Helsinn Therapeutics (U.S.) Inc., and Helsinn Advanced Synthesis SA).
• Roche Palo Alto LLC — the Palo Alto research entity of Roche (successor to Syntex, which originated palonosetron; see U.S. 5,202,333). Status: operating (Roche group), but it exited the palonosetron estate in 2016 (see timeline).

Both original assignees ship / are part of organizations that ship products; neither is a licensing-only shell.

Assignment timeline

Critical disclosure: As explained in the source note, I can confirm parties, conveyance types, and dates from Google Patents' legal-event records, but the reel/frame and correspondent fields were not retrievable for the '905-specific entries. I list reel numbers only where independently documented, and I mark gaps rather than fill them.

1. 2015-01-15 (executed) / recorded 2015-01-15 — Reel/Frame: not retrievable

• Conveyance: Assignment (initial inventor→employer)
• Assignor: Thomas Malefyt; Andrew Miksztal; Kathleen M. Lee
• Assignee: Roche Palo Alto LLC
• Correspondent: not retrievable from available sources
• Context: Routine pre-filing/contemporaneous assignment of the three Roche-legacy inventors' rights to their employer, filed with the 14/597,489 continuation.

2. 2015-01-15 (executed) / recorded 2015-01-15 — Reel/Frame: not retrievable

• Conveyance: Assignment (initial inventor→employer)
• Assignor: Giorgio Calderari; Daniele Bonadeo; Roberta Cannella; Giulio Macciocchi; Simone Macciocchi; Carmine Panuccio
• Assignee: Helsinn Healthcare SA
• Correspondent: not retrievable from available sources
• Context: Same-day companion recording covering the Helsinn-side inventors (Giulio/Simone Macciocchi standing in for the deceased Alberto Macciocchi) and family-wide applications filed together.

3. 2016-05-11 (executed) / recorded 2016-05-11 — Reel/Frame: not retrievable

• Conveyance: Assignment
• Assignor: Roche Palo Alto LLC
• Assignee: Helsinn Healthcare SA
• Correspondent: not retrievable from available sources
• Context: Internal consolidation — Roche's remaining co-ownership interest transferred to Helsinn, giving Helsinn 100% of the palonosetron formulation estate. Roche's exit, not a fire-sale.

4. 2018-11-14 (executed) / recorded 2018-11-14 — Reel 047534 / Frame 0024 (reel/frame corroborated by the 2018-11-21 corrective-assignment record, which expressly states "PREVIOUSLY RECORDED ON REEL 047534 FRAME 0024")

• Conveyance: Assignment — recorded as a "Patent Co-Ownership Agreement"
• Assignor: Helsinn Healthcare SA
• Assignee: Helsinn Advanced Synthesis SA; Helsinn Therapeutics (U.S.), Inc.; Helsinn Birex Pharmaceuticals Ltd.
• Correspondent: not retrievable
• Context: Internal corporate reorganization — title spread across Helsinn group operating subsidiaries (API synthesis, U.S. commercial, Irish manufacturing). Not a transfer to an unrelated party.

5. 2018-11-21 (executed) / recorded 2018-11-21 — Reel/Frame: not retrievable (corrects Reel 047534/0024)

• Conveyance: Corrective Assignment
• Assignor: Helsinn Healthcare SA
• Assignee: Helsinn Birex Pharmaceuticals, Ltd.; Helsinn Therapeutics (U.S.), Inc.; Helsinn Advanced Synthesis SA
• Correspondent: not retrievable
• Context: Administrative correction — fixes the spelling of "Helsinn Birex Pharmaceuticals Ltd." and assignee addresses on the 2018-11-14 recording. No change in beneficial ownership.

6. 2022-12-30 (executed) / recorded 2022-12-30 — Reel/Frame: not retrievable

• Conveyance: Security Interest (security agreement — a lien, not a title transfer)
• Assignor: Helsinn Birex Pharmaceuticals Limited; Helsinn Healthcare SA; Helsinn Therapeutics (U.S.), Inc.
• Assignee: Hamilton SA LLC (secured party)
• Correspondent: not retrievable
• Context: Securitization — the Heslinn group pledged the patent as collateral for financing. This is the only non-Helsinn name to ever appear in the chain, and it never took title.

7. 2023-09-20 (executed) / recorded 2023-09-20 — Reel/Frame: not retrievable

• Conveyance: Release by Secured Party
• Assignor: Hamilton SA LLC (releasing)
• Assignee: Helsinn Healthcare SA; Helsinn Birex Pharmaceuticals Limited; Helsinn Therapeutics (U.S.), Inc.
• Correspondent: not retrievable
• Context: Termination of the securitization — lien discharged; title reverts cleanly to the Helsinn group.

Corroborating family-wide reel/frame context (from the § 3.73(c) terminal disclaimer reproduced in PTAB records — these cover sibling patents, not '905): '724 patent — Reel 017831/0234 (2006-06-21) and Reel 025450/0180 (2010-12-06); '424 patent — Reel 025816/0283 and 025816/0579 (2011-02-16); '725 patent — Reel 025819/0244 and 025819/0334 (2011-02-16); app. 13/087,012 — Reel 028899/0100 (2012-09-05) and Reel 029302/0296 (2012-11-15); app. 13/901,288 — Reel 030478/0304 (2013-05-23); app. 13/901,437 — Reel 030478/0960 and Reel 030479/0001 (2013-05-23). The consistent Helsinn Healthcare SA + Roche Palo Alto LLC pairing across these reels confirms the two-party structure described above. No reel is cited in that document for '905 or its immediate parent 13/902,299.

Timeline diagram

timeline
    title Ownership of US 9125905
    2003 : Priority application filed
    2004 : PCT application filed
    2015 : Patent issued to Helsinn and Roche Palo Alto
         : Inventor assignments recorded
    2016 : Roche Palo Alto interest transferred to Helsinn
    2018 : Co-ownership spread to Helsinn affiliates
         : Corrective assignment recorded
    2022 : Security interest to Hamilton SA LLC
    2023 : Security interest released
    2024 : Patent expires

NPE / troll-pattern signals

1. Shell-entity transfer — NOT PRESENT. Every assignee in the chain is a named Helsinn or Roche operating entity (Reels/entries of 2015-01-15, 2016-05-11, 2018-11-14, 2018-11-21). No "IP / Holdings / Ventures / Licensing" successor appears; no single-member Delaware or Texas LLC takes title. The one third-party name, Hamilton SA LLC (2022-12-30), took a security interest, not title, and released it on 2023-09-20.

2. Known asserter in the chain — NOT PRESENT. No assignee matches Acacia, Marathon, Intellectual Ventures, IPNav, Wi-LAN, Conversant/Mosaid, Vringo, Pendrell, Round Rock, Erich Spangenberg entities, or any Unified Patents / RPX high-frequency-plaintiff listing. The record plaintiff in every action is Helsinn Healthcare S.A. (with Roche Palo Alto LLC pre-2016) — the original assignee and the Aloxi/Akynzeo marketer.

3. Repeat correspondent across the chain — UNCLEAR (no data). The correspondent-of-record field could not be retrieved for any '905 entry, so recurrence cannot be tested. I note only that nothing in the available record — no shared registered-agent address, no anonymous-LLC pattern — gives the correspondent signal anything to attach to. This is a data gap, not a negative finding.

4. Cascading transfers — NOT PRESENT. Seven recorded events span 2015 through 2023 (roughly eight years), and the two 2018 entries are 7 days apart and are a recording plus its own correction. There is no sequence of chained LLCs; every 2018 step is inside the Helsinn corporate family.

5. Pre-litigation transfer — NOT PRESENT. The first infringement suits over this family were filed in 2011–2013 (D.N.J. 11-cv-03962 filed 2011-07-08; D. Del. 13-688 filed 2013-04-16; D.N.J. 13-5815 filed 2013-09-30), predating the 2016 Roche→Helsinn consolidation. The suits assert against ANDA filers (Teva, Dr. Reddy's, Sandoz, Cipla, Mylan, Accord, Aurobindo, Ben Venue/Bedford, Exela, Hospira). No assignment was arranged to enable or venue the assertion.

6. Bankruptcy fire-sale — NOT PRESENT. No Chapter 7/11 anywhere in the chain. Helsinn's 2022 collateral pledge was to Hamilton SA LLC and was released on 2023-09-20 — the mark of an ordinary secured financing paid off, not a distressed sale. The patent's status is Expired – Lifetime with anticipated expiration 2024-01-30 (natural term, not an abandonment).

7. Privateering — NOT PRESENT. No operating company is funding a separate NPE to assert against competitors here. The owner is the plaintiff, and it asserts against generic challengers to its own marketed product.

8. Defensive aggregator — NOT PRESENT. The chain does not terminate at RPX, AST, LOT, Unified Patents, or OIN; it terminates back at the Helsinn group.

Verdict

Operating-company assertion.

Justification: the '905 patent was issued to and remains held by Helsinn Healthcare SA — an operating drug company that obtained FDA approval for Aloxi® (palonosetron HCl injection, NDA 21-372, approved 2003-07-25), a product embodying the claims — together with Roche Palo Alto LLC until the 2016-05-11 consolidation. The only interludes involving a non-Helsinn party are the internal co-ownership spread across Helsinn group entities (2018-11-14, Reel 047534/0024, and its 2018-11-21 correction) and a secured financing to Hamilton SA LLC (2022-12-30) that was released the following year (2023-09-20). The patent has been asserted only in Hatch-Waxman actions by the owner against generic-competitor ANDA filers (D.N.J. 11-cv-03962, 2011-07-08; D. Del. 13-688, 2013-04-16; D.N.J. 13-5815, 2013-09-30; and the 2015 New Jersey and Delaware cases), which is operating-company assertion, not NPE activity.

Verification: search by patent number at the USPTO Assignment Center — https://assignmentcenter.uspto.gov/ (legacy interface: https://assignment.uspto.gov/patent/index.html). The '905-specific reel/frame and correspondent fields should be read from that system directly, since I could not retrieve them here.

I'll research this systematically. Let me start with searches on the patent and its cited prior art.

I have the patent text and citation lists. Let me verify details on the most relevant cited references, starting with the key palonosetron disclosure.

US 9,125,905 — Prior‑Art Analysis of Record Citations

1. Patent identification (verified)

Source: Google Patents US9125905 (full text supplied in the prompt is authoritative).

Important note on the USPTO request: the authoritative full text, the Google Patents record, and DrugPatentWatch (link) all confirm the same bibliographic data for 9125905. I did not complete a separate PatentCenter screen within this session, so the citation/date data below is taken from the patent's own "Citations" table, which is the record of what the examiner and third parties actually cited.

2. The claims that must be met for § 102 (essential for the analysis)

This is a narrow, late‑generation claim set (9 claims) — not the broad genus claims of the original family patents:

• Claim 1 – A formulation comprising a sterile aqueous intravenous solution comprising palonosetron or salt in an amount of 0.25 mg and a concentration of 0.03–0.2 mg/mL (free‑base basis).
• Claim 2 – pH 4–6. Claim 3 – pH 5.0 ± 0.5.
• Claim 4 – Method of manufacturing a finished container: (a) provide open container; (b) fill with aqueous IV solution of palonosetron 0.25 mg at 0.03–0.2 mg/mL; (c) seal; (d) terminally sterilize the sealed, filled container.
• Claims 5–6 – pH 4–6 / 5.0 ± 0.5 for the method.
• Claim 7 – Finished container made and terminally sterilized by the process of claim 4.
• Claims 8–9 – pH limitations for the container.

Every § 102 analysis below must be tested against these exact elements (0.25 mg; 0.03–0.2 mg/mL; sterile aqueous IV solution; option of terminal sterilization and pH 4–6).

3. Which citations legally qualify as § 102 prior art

Because the effective date is 30 Jan 2003, only art published/patented before that date (or a US patent/US published application filed before the applicant's invention under pre‑AIA § 102(e)) can be § 102 art. On that basis:

• Pre‑2003 art (can be § 102 or § 103): US 4,695,578; US 4,753,789; US 4,886,808; US 4,906,755; US 4,937,247; US 5,011,846; EP 0512400; US 5,202,333; US 5,240,954; US 5,272,137; US 5,344,658; US 5,578,632; US 5,622,720; US 5,854,270; US 5,955,488; US 6,132,758; US 6,284,749; US 2001/0020029; US 6,287,592; US 2003/0095926.
• Post‑2003 publications of post‑2003‑priority applications (NOT § 102; at most § 103/OTDP or § 102(e) if a pre‑2003‑filed US case): WO 03/100091 (pub. 2003‑12‑04); WO 2004/045615 (pub. 2004‑06‑03; priority 2002‑11‑15); US 2004/0147510 (pub. 2004‑07‑29; filed 2003‑01‑13 — could be § 102(e)); WO 2004/067005 and WO 2004/073714 (applicant's own family); US 6,699,852 (granted 2004‑03‑02, filed 2000‑12‑20 — possible § 102(e)); US 7,109,339 (granted 2006‑09‑19, filed 2002‑12‑19 — possible § 102(e)).
• Applicant's own family members (not prior art): US 7,947,724; US 7,947,725; US 7,960,424; US 8,518,981; US 8,598,218; US 8,598,219; US 8,729,094; US 2013/0261149; US 2013/0261150; US 2013/0289065; US 2014/0039000; US 2013/0261150 (= US 2013/0261150 A1, Giulio Macciocchi).

4. Reference‑by‑reference analysis

Below is each patent citation, with full citation, dates, description, and its realistic § 102 exposure against claims 1–9. Because the two independent claims require palonosetron specifically at 0.25 mg / 0.03–0.2 mg/mL (plus terminal sterilization in the method/container claims), the honest conclusion is that none of the cited references anticipates any claim. Each entry explains which claim (if any) could be argued and why it fails.

A. The 5‑HT₃‑antagonist compound/use patents (ondansetron, granisetron, dolasetron)

B. The ondansetron/granisetron formulation patents (most relevant to claims 1–9 in theory)

C. The palonosetron reference (the single most relevant citation)

US 5,202,333 A — Syntex (U.S.A.) Inc. — priority 1989‑11‑27, granted 1993‑04‑13 — "Tricyclic 5‑HT₃ receptor antagonists" (inventors: Clark, Berger, Smith, Weinhardt, Eglen; current assignee Roche Palo Alto LLC) — Google Patents.

• This is the compound patent that first discloses palonosetron (RS‑25259‑197) and, in Example 13, a representative IV solution: Compound of Formula I 10–100 mg; dextrose monohydrate q.s. to isotonic; citric acid monohydrate 1.05 mg; sodium hydroxide 0.18 mg; water for injection to 1.0 mL; pH 3.7.
• § 102 against claims 1–9: None. Example 13 is a 10–100 mg/mL solution (i.e., 10,000–100,000 µg/mL), not 0.03–0.2 mg/mL; there is no 0.25 mg unit dose, no EDTA, no mannitol, no pH 4–6, and no terminal sterilization. The patent itself (col. 1) states this Example 13 formulation "has a pH of 3.7 and a shelf stability of less than the 1‑2 year time period required by health authorities."
• It is, however, the primary § 103 reference — the entire litigation record (Helsinn v. Dr. Reddy's/Teva/Sandoz, D.N.J. 3:11‑cv‑03962; IPR2015‑01550 series) and the foreign prosecution (e.g., the Colombian decision in the search results: "D1 enseña una solución para inyección que comprende palonosetrón clorhidrato… Ejemplo 13") turns on Example 13 as the starting point.
• Also cited in the family: US 5,517,486 / US 5,567,818 (Syntex, processes/intermediates for the benz[de]isoquinolinone).

D. Non‑palonosetron 5‑HT₃ / serotonin ligand chemistry

E. Post‑priority publications and applicant's own family (cannot be § 102 art)

F. Additional references appearing in the broader "Patent Citations (44)" list

Also cited (same analysis as their genus): US 4,929,632, US 5,034,398, US 5,360,800 and US 6,284,770 (alosetron genus, Glaxo), US 5,578,628, US 5,922,749, US 6,063,802, US 5,924,749, US 5,922,749 (ondansetron family), US 6,294,548, US 5,922,749, plus applicant's own US 7,947,724; US 7,947,725; US 7,960,424; US 8,518,981; US 8,598,218; US 8,598,219; US 8,729,094 and publications US 2013/0261149; US 2013/0289065; US 2014/0039000; US 2013/0261150.

5. Bottom line

No reference cited on the face of US 9,125,905 anticipates any of claims 1–9 under 35 U.S.C. § 102. The claims are limited to a palonosetron sterile aqueous IV solution at 0.25 mg / 0.03–0.2 mg/mL (and a terminal‑sterilization manufacturing/container aspect), and no single cited reference discloses all elements:

1. US 5,202,333 A (Syntex/Berger) is the only cited reference that discloses a palonosetron IV formulation (Example 13), but at 10–100 mg/mL, pH 3.7, with dextrose/citric acid and no EDTA/mannitol/terminal sterilization. It is the key § 103 primary reference, not a § 102 anticipation.
2. The US 4,695,578 / 4,753,789 / 4,886,808 / 4,906,755 / 4,937,247 / 5,011,846 / 5,240,954 / 5,344,658 / 5,578,632 / 5,622,720 / EP 0512400 group are ondansetron/granisetron/dolasetron genus/use patents — wrong active, § 103 background only.
3. US 5,854,270; US 5,955,488; US 6,132,758; US 6,284,749; US 2001/0020029; US 6,294,548; US 5,272,137; US 6,287,592 disclose formulation technology (citrate buffers, EDTA chelation, tonicifiers, vials, freeze‑drying, stabilization) but not palonosetron — § 103 art only (this is exactly how petitioners deployed them: Berger as primary reference combined with Castillo/US 6,284,749 for EDTA, Kibbe for citrate buffer, and PDR entries for mannitol/tonicity).
4. WO 03/100091; WO 2004/045615; US 2004/0147510; WO 2004/067005; WO 2004/073714; US 6,699,852; US 7,109,339 are post‑2003‑01‑30 publications and/or the applicant's own family — legally incapable of § 102 anticipation against these claims (relevant, if at all, only for § 102(e), § 103, or obviousness‑type double patenting).

Stated candidly: the value of this citation list to a challenger is the § 103 obviousness combination anchored on US 5,202,333, not any § 102 anticipation. That framing matches the real‑world record for this family (the D.N.J. litigation and the IPR2015‑01550/01551/01553/01554 petitions concerning the sibling patents US 8,729,094 / 9,173,942).

Caveat on data provenance: bibliographic dates above are as printed in the patent's own citation tables (Google Patents record for US 9,125,905 and the corroborating Justia listing); I did not independently re‑verify each individual reference on USPTO PatentCenter in this session, so a few grant/priority dates should be spot‑checked before being relied on in a filing.

I'll verify key prior-art references and any PTAB/validity record before drafting the § 103 analysis.

Obviousness Analysis — US 9,125,905 B2 under 35 U.S.C. § 103

Building on the prior sections: the claim-scope, bibliographic, and litigation material already generated is assumed. This section does not re-state it; it uses it. Where the prior section flagged uncertainty, I confirm or refine it below rather than repeat it.

1. Governing framework and effective date

The analysis below applies the Graham v. John Deere / KSR Int'l v. Teleflex framework: (a) scope and content of the prior art; (b) differences between the prior art and the claims; (c) level of ordinary skill; (d) secondary considerations.

Which § 103 applies. The '905 application (14/597,489) was filed Jan 15, 2015, but every claim is supported by the Jan 30, 2003 disclosure (the 5 mL/0.25 mg/0.05 mg/mL embodiment appears verbatim in the 2003 specification: "the palonosetron is supplied in vials that comprise 5 ml. of solution, which equates to about 0.25 mg of palonosetron at a concentration of about 0.05 mg/ml"). On that basis pre-AIA § 103 governs with a Jan 30, 2003 critical date. I flag one caveat: sibling US 8,598,219 was held by the Supreme Court to be "governed by the AIA" by virtue of its effective date (Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc., 586 U.S. ___ (2019), slip op. at 3 — https://www.ctbar.org/docs/default-source/education/materials/2019-2020-materials/eip200210-ip-year-in-review-final-materials.pdf). If the USPTO applied the same AIA transition logic (the "Jedi Master Mixer" rule) to the '905 lineage, AIA § 103 would apply instead. This makes no practical difference here: every reference relied on below predates Jan 30, 2003 and therefore qualifies under either § 102 regime.

Excluded from the combination: WO 2004/045615 A1 (Helsinn, priority Nov 15, 2002) and WO 2004/067005 A1 (the family's own PCT). As commonly-owned § 102(e) art, the former is disqualified for § 103 purposes under pre-AIA § 103(c) (and § 102(b)(2)(C) under the AIA). I do not rely on it.

2. What must be shown, limitation by limitation

Key observation for § 103: Claim 1 is remarkably thin — only three substantive limitations. Claims 4–9 add nothing beyond (a) the mechanical fill/seal/terminal-sterilize sequence and (b) a pH value the patent itself describes as the optimum of a routine screen ("The results indicated that palonosetron hydrochloride is most stable at pH 5.0", Ex. 1; "most optimally about 5.0"). That is the classic In re Aller fact pattern (220 F.2d 454 (CCPA 1955)) — discovery of the optimum of a result-effective variable.

3. Level of ordinary skill (POSA)

A POSA here is a pharmaceutical formulator (M.S./Ph.D. in pharmaceutics or pharmaceutical chemistry, or Pharm.D. with formulation experience) with ~2–5 years in parenteral product development, conversant with Remington's, the Handbook of Pharmaceutical Excipients, Trissel's Handbook on Injectable Drugs, and standard preformulation doctrine (pH-rate profiling, buffer selection, tonicity, chelation, terminal sterilization). This is the level DRL's own IPR expert (Dr. DeLuca) described — experimental design and pH/chelate screening being "highly standard and routine" (https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1458462](/patent/1458462)/download-documents?artifactId=eP8zaAsglfTztXlM2WdyjGwjtXFr7GondKHQGeeuO-Jj2yP-W5EYnDk).

4. The prior-art set on the face of the '905

5. The obviousness combinations

Combination A — primary attack on claims 1–3 (composition + pH)

US 5,202,333 (Berger) + Tang 1998 (palonosetron Phase II IV dose-ranging) + Trissel / the setron injectable labels + Handbook of Pharmaceutical Excipients.

• Berger supplies the drug, the salt, the IV/single-unit solution, the citrate/NaOH vehicle — and a concentration genus that literally embraces 0.03–0.2 mg/mL (0.003–0.02 % w/v sits inside Berger's ≈0.000001–10 % w/v genus). Under In re Peterson, 315 F.2d 817 (CCPA 1963), and In re Woodruff, 919 F.2d 1575 (Fed. Cir. 1990), a claimed range falling within a disclosed range is prima facie obvious absent criticality.
• Tang 1998 (RS-25259 in PONV, 0.1–30 µg/kg IV in 15 mL) converts to 0.007–2.1 mg amounts and 0.0005–0.14 mg/mL concentrations — a range that brackets both the 0.25 mg amount and the 0.05 mg/mL point, and Tang taught an IV bolus over ~30 seconds in an isotonic vehicle. (Tang's conversion analysis appears in DRL's IPR petitions: https://ptacts.uspto.gov/ptacts/public-informations/petitions/1458462/download-documents?artifactId=uMzzOWis5KDF75B3RSeTv7etCYtqgXEy0lmENdOsBckuidUy77GJStQ.)
• Trissel and the ondansetron/granisetron injectable art supply the reason to work in the acidic/pH-buffered range, and the Handbook of Pharmaceutical Excipients supplies citrate and mannitol as ordinary selections.
• Motivation: the '905 specification itself concedes the problem and the incentive — Berger Example 13 "has a pH of 3.7 and a shelf stability of less than the 1-2 year time period required by health authorities." A POSA seeking a commercially viable palonosetron IV would necessarily (i) pick a unit dose from the clinically studied range, (ii) pick a market-appropriate fill volume (integer mL, i.e., 5 mL), and (iii) run a pH screen. That is exactly what Examples 1–2 of the patent do.

Combination B — method claims 4–6 and product-by-process 7–9

Combination A + US 6,294,548 (or JPS 57-206447 / US 5,597,530 / US 5,437,964).

• The claim-4 sequence (open container → fill → seal → terminally sterilize) is disclosed as a known, preferred manufacturing scheme for parenteral setrons. US 6,294,548 expressly autoclaves sealed glass vials of a granisetron solution (15–60 min at 121 °C); US 5,597,530 does the same for pre-filled syringes; JPS 57-206447 does it for liquid drug in a plastic container; the '905's own Example 8 container closure (multilayer polyethylene bag + isoprene stopper) is consistent with that art.
• Motivation: regulatory preference for terminal sterilization over aseptic fill, plus the stated advantage of avoiding aseptic manufacture — an economic/regulatory, not technical, design choice. KSR at 1742 (design incentives and market forces).
• Note that the '905 method claims do not require a non-aseptic environment, do not require any particular sterilizing modality, and do not require achieving a stated shelf life — the "stable for 24 months" hook that the family's other patents used was given no patentable weight during prosecution (see the applicant's own summary of the examiner's position at https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1458461](/patent/1458461)/download-documents?artifactId=WmFPbYPBQl-7OvU3avg-SLUMlFS6JgaFB-3qDC3b-Y7A4smki2C5qhI). So there is nothing left in claims 4–9 beyond the routine sequence plus pH.

Combination C — the pH edges (claims 3, 6, 9)

Won 1995 + Connors + Wells + setron labels + the patent's own Ex. 1. A pH-rate profile is the single most standard preformulation exercise. Choosing 4–6, then narrowing to 5.0 ± 0.5 as the observed optimum, is In re Aller routine optimization of a result-effective variable. DRL's petition noted that commercial setron injectables span pH ≈3.0–7.3 (citing Trissel at 680), so the claimed window overlaps the known, workable window. Under In re Peterson, moreover, 4–6 is substantially overlapped by Berger's pH 3.7 and physiological 7.4 endpoints.

Combination D — the buffer/chelator/tonicity architecture (relevant to the family generally and to claim 7's container)

Berger (citric acid/NaOH) + US 6,294,548 (citrate buffer) + Akers 2002 (EDTA for trace-metal-catalyzed oxidation) + Handbook of Pharmaceutical Excipients (mannitol, citrate, EDTA) + Won 1995 (oxidative degradation of an antiemetic). Each excipient answers a known problem: citrate = buffer identity and pH control during heat sterilization; EDTA = oxidative stabilization; mannitol = tonicity. All had known use levels. This combination is directly on point for the family's broader claims (e.g., '219/'424) and supplies context/expectation for the narrower '905 claims.

6. Claim-by-claim vulnerability

7. Motivation and reasonable expectation of success (the KSR articulation)

1. Same field, same problem, same class. Berger, Tang, the ondansetron/granisetron patents/labels, and Trissel all address injectable 5-HT₃-antagonist antiemetics. The art is not analogous-art-contested.
2. The problem was recognized and the solution path was laid out. The specification's own Background frames the deficiency (Berger Ex. 13 → "less than the 1-2 year" shelf-life) and the remedy ("adjusting the formulation's pH and/or excipient concentrations").
3. Finite, predictable options. For each variable there were only a handful of pharmaceutically acceptable choices: buffers (citrate/acetate/phosphate — citrate already in Berger Ex. 13 and in the granisetron injectable), chelators (EDTA/edetate, and citrate itself), tonicity agents (NaCl/dextrose/mannitol), pH 3.7–7.4, and fill volumes in integer mL. KSR at 1740 ("a finite number of identified, predictable solutions").
4. The patent's own Examples 1–3 are routine-optimization evidence. Ex. 1 is a four-point pH screen at 80 °C; Ex. 2 is a 24-lot experimental-design screen of palonosetron/citrate/EDTA ranges using commercial DoE software; Ex. 3 is a two-arm tonicity-agent comparison. A POSA would have run those same experiments. In re Aller; Pfizer v. Apotex, 480 F.3d 1348 (Fed. Cir. 2007) ("obvious to try" where there is a reasonable expectation of success).
5. Expected results, not unexpected ones. Choosing pH 5 to slow hydrolysis, adding EDTA to suppress metal-catalyzed oxidation, swapping NaCl for mannitol to slow degradation, and terminally sterilizing a heat-stable solution to avoid aseptic fill are all predictable improvements — the Kao/Aller line requires something more than expected improvement to rebut.

8. Where the § 103 case is genuinely weak (and how the patent owner fights)

These are the points a patent owner (and, historically, Helsinn) pressed. I set them out fairly, since they materially affect confidence:

1. "No reason to select 0.25 mg." DRL itself admitted in its IPR petitions: "Neither [Berger nor Eglen] teaches the specific concentration, the pH range claimed, the use of mannitol instead of dextrose, or the specific amount of claim 2." DRL's own expert called Berger's dose range "huge" and testified Example 13's 10–100 mg was "40- to 400-times larger than the claimed 0.25 mg dose." That admission cuts against a clean obviousness case on the amount limitation. (https://ptacts.uspto.gov/ptacts/public-informations/petitions/1458462/download-documents?artifactId=2CK0bEKmr_KAlOwh_27WDRKr6EB0amlcSagvEnyhudGT5vFZsZpykhs)
2. Alleged teaching away by Tang. Helsinn argued that Tang 1998 would have taught a POSA that 0.05 mg/mL / 0.25 mg was ineffective in treating emesis (the efficacy plateau being at higher doses), i.e., a direction away from the claimed species. If credited, that is a Wm. Wrigley Jr. Co. v. Cadbury (Fed. Cir. 2010) teaching-away argument. I have only Helsinn's characterization of Tang, not the paper itself — treat this as a party argument, not established fact.
3. Unexpected stability at low concentration. The specification's Ex. 2 states "greatest stability seen at the lowest palonosetron concentrations," and the applicant argued in prosecution that this was "unexpected stability of compositions comprising palonosetron hydrochloride at the presently claimed concentration of 0.05 mg/mL." If the art really taught that lower concentrations degrade faster, this is a genuine unexpected-results rebuttal.
4. Judicial credit for secondary considerations. The Sandoz/DRL bench trial found the family's asserted claims (of '724/'725/'424/'219) valid, non-obvious, with commercial success and long-felt need favoring non-obviousness (D.N.J. Nov. 13, 2015, https://www.finnegan.com/a/web/56530/2G4oFc/20151113_311cv03962_helsinn_v_teva_di360_memorandum_opinionpd.pdf; summary at https://www.robinskaplan.com/printpilot-publication-resources-legal-updates/generically-speaking-hatch-waxman-bulletin-2015-generically-speaking-winter-2015-helsinn-healthcare-sa-v-dr-reddys-labs-ltd2.pdf). Important caveats: that decision did not adjudicate the '905 (which issued Sept 8, 2015, mid-trial), and it was never reached on appeal — the Federal Circuit reversed on the on-sale bar (Helsinn v. Teva, 855 F.3d 1356 (Fed. Cir. 2017)), and the Supreme Court affirmed on § 102(a)(1) (Helsinn, 586 U.S. ___ (2019)). The non-obviousness finding was therefore superseded as to those patents by a § 102 holding, and provides only persuasive, not binding, support for the '905.

Nexus caveat: the district court's secondary-considerations reasoning centered heavily on the 0.25 mg dose selection and Aloxi®'s commercial success as a product. Because claim 1 recites the 0.25 mg amount, nexus is stronger than in a typical "formulation-only" case — but a court could still find the success attributable to the active ingredient's half-life and the dosing regimen, not to the 0.03–0.2 mg/mL band or the sterilization method.

9. Bottom line and confidence

• Most vulnerable: claims 3, 6, 9 (pH 5.0 ± 0.5). The patent's own Example 1 characterizes this as the optimum of a routine pH screen — near-conceding In re Aller obviousness. Claims 2, 5, 8 (pH 4–6) fall for the same reason plus Peterson overlap with Berger's 3.7 and physiological 7.4.
• Very vulnerable: claims 4, 7 (fill/seal/terminally sterilize). The same sequence, on the same class of drug, in a sealed glass vial, is expressly taught in US 6,294,548 and in the terminal-sterilization art cited on the '905 face.
• Contested: claims 1 (and by incorporation 4, 7). The only real battleground is the combination of the 0.25 mg amount with the 0.03–0.2 mg/mL band. Berger's genus embraces the concentration; Tang's studied range brackets the amount and concentration; the 5 mL integer-volume unit dose is the market-driven volume. That is enough for a prima facie case under Peterson/KSR, but a teaching-away or unexpected-results rebuttal aimed at Tang 1998 and at the Ex. 2 concentration-stability data has real force.
• Overall: a competent challenger would plead § 103 as Berger + Tang 1998 + US 6,294,548 (granisetron injectable) + Akers 2002 + Handbook of Pharmaceutical Excipients + US 5,597,530/JPS 57-206447, and would likely prevail on claims 2–9 while facing a genuine fight on the 0.25 mg/0.05 mg/mL species of claim 1.

Confidence and explicit limits.

• High confidence: the claim text and limitation mapping; the teaching content of US 5,202,333 Example 13 (pH 3.7, citric acid/NaOH, 10–100 mg) as both the patent and DRL's petitions describe it; US 6,294,548's citrate buffer + 121 °C autoclaving of sealed vials; I found no PTAB or Federal Circuit adjudication of the validity of US 9,125,905 itself (the family's IPRs — IPR2015-01550/-01551/-01553/-01554 — were against US 8,729,094, and I found no '905-specific proceeding). This confirms, rather than contradicts, the earlier-generated uncertainty note.
• Moderate confidence: the precise numerical content of the Tang 1998 and Won 1995 references; I am relying on secondary characterizations (Helsinn's PTAB responses and DRL's petitions) for the dose/concentration conversions, not on the primary papers.
• Not asserted: any holding that the '905 claims have been adjudicated invalid or valid. On the record I can reach, they have not been — the family's invalidity came from the § 102 on-sale bar against US 7,947,724 / 7,947,725 / 7,960,424 / 8,518,981, not from a § 103 judgment against the '905.
• Contradiction flagged: none with the prior sections. The one point I would refine is the prior section's notation that the '905 is "terminal-disclaimer-linked"; the record I reviewed shows terminal disclaimers being filed in this family against co-pending application 14/052,925, but I did not verify a disclaimer specific to 14/597,489 and therefore would not state it as established.